NCT00499681

PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE

A Phase II Neo-Adjuvant Study of Letrozole in Combination With Lapatinib in Post -Menopausal Patients With HER2-Positive and Hormone Receptor-Positive Operable Breast Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Vanderbilt-Ingram Cancer Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving letrozole together with lapatinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This randomized phase II trial is studying how well giving letrozole together with lapatinib works in treating postmenopausal women with stage I, stage II, or stage III breast cancer that can be removed by surgery.

Detailed description

OBJECTIVES: Primary * To determine the pathological complete response in patients with HER2-positive and hormone receptor-positive operable stage I-III breast cancer. Secondary * To determine tumor cell apoptosis in situ as measured by TUNEL analysis of tumor sections from fresh frozen or paraffin-embedded core biopsies. (Parts 1 and 2) * To determine whether EGFR, P-EGFR, P-HER2, Ser118 P-ERα, P-Akt, and P-MAPK (by IHC using fresh frozen or paraffin-embedded core biopsies) predict the inhibition of proliferation in situ (Ki67) and/or induction of cell death (TUNEL). (Parts 1 and 2) * To determine the safety profile of neoadjuvant letrozole and lapatinib. (Part 2) * To evaluate tumor response to treatment as measured by ultrasound. (Part 2) * To evaluate the rate of breast conservation surgery. (Part 2) * To determine the inhibition in cell proliferation in situ in response to letrozole and lapatinib as measured by the change in percentage of Ki67-positive tumor cells (determined by IHC using tumor sections from fresh frozen or paraffin-embedded surgical material). (Part 2) OUTLINE: This is a randomized, double-blind, placebo-controlled, two-part study. * Part 1: Patients are randomized to treatment arm. * Patients receive lapatinib and letrozole once daily for 2 weeks. * Patients receive letrozole and placebo once daily for 2 weeks. Patients then proceed to part 2. * Part 2: All patients receive lapatinib and letrozole once daily for 14 weeks. Patients then undergo surgical resection of disease. Patients undergo tissue sample collection at baseline, at 2 weeks, and then at the time of surgery for biomarker and laboratory studies. Samples are analyzed by IHC and TUNEL.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	lapatinib ditosylate	Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II
DRUG	letrozole	Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks
OTHER	placebo	Given once daily for 2 weeks

Timeline

• Start date: 2007-07-01
• Primary completion: 2009-10-01
• Completion: 2010-12-01
• First posted: 2007-07-11
• Last updated: 2012-08-10
• Results posted: 2012-07-10

Locations

4 sites across 1 country: United States